Credit Suisse Cuts Rating on Maravai LifeSciences Amid Slowing Growth
June 24, 2023
☀️Trending News
Maravai ($NASDAQ:MRVI) LifeSciences, a biotechnology company focused on providing services for the development and production of biologics and gene therapies, recently received a downgrade in rating from Credit Suisse. Credit Suisse now rates Maravai LifeSciences as “neutral” due to a slowdown in growth. Its services include process development, clinical manufacturing, cell line engineering, and commercial manufacturing, among others. The company also offers specialized consulting and engineering services to ensure efficient and cost-effective delivery of high-quality drugs to market.
Maravai LifeSciences is headquartered in San Diego, California, and has additional locations in the United States, Europe, and Asia. The recent downgrade in rating from Credit Suisse is due to a slowdown in the company’s growth. Despite the rating, Maravai LifeSciences remains committed to providing quality services to its clients and remains optimistic about its future growth prospects.
Share Price
On Tuesday, Credit Suisse downgraded MARAVAI LIFESCIENCES shares citing their slowing growth in recent quarters. The stock opened at $12.9, but closed at $13.6, representing a 0.3% gains from prior closing price. This downgrade reflects a downward trend in MARAVAI LIFESCIENCES’ performance as growth has been slowing over the past few quarters.
Additionally, Credit Suisse analysts believe that this stock is currently overvalued and may face further downside if earnings fail to rebound. As such, investors should exercise caution when considering investments in MARAVAI LIFESCIENCES. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Maravai Lifesciences. More…
| Total Revenues | Net Income | Net Margin |
| 717.73 | 153.28 | 21.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Maravai Lifesciences. More…
| Operations | Investing | Financing |
| 458.75 | -95.76 | -166.19 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Maravai Lifesciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.32k | 1.41k | 3.96 |
Key Ratios Snapshot
Some of the financial key ratios for Maravai Lifesciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 83.4% | 185.6% | 57.1% |
| FCF Margin | ROE | ROA |
| 60.8% | 48.0% | 11.1% |
Analysis
At GoodWhale, we have conducted an analysis of MARAVAI LIFESCIENCES‘s financials. According to our Risk Rating, it is a medium risk investment in terms of financial and business aspects. We have detected 3 risk warnings in income sheet, balance sheet, cashflow statement. If you register with us, you will have access to these findings and gain insight into potential risks associated with MARAVAI LIFESCIENCES. We believe that having an understanding of the risks is essential in making the best possible investments. With our analysis, you can have the peace of mind that your investments are based on sound advice and information. More…
Peers
The competition between Maravai LifeSciences Holdings Inc and its competitors is fierce. Takara Bio Inc, Forward Pharma A/S, Obio Technology (shanghai) Corp Ltd are all trying to gain market share in the rapidly growing life sciences market. Maravai LifeSciences Holdings Inc has a strong product portfolio and is well-positioned to compete in this market.
– Takara Bio Inc ($TSE:4974)
Takara Bio Inc. is a Japanese biotechnology company that specializes in the development, manufacturing, and marketing of biotechnology products. The company was founded in 1953 and is headquartered in Kyoto, Japan. Takara Bio has four main business segments: biopharmaceuticals, bio-agriculture, bio-industry, and diagnostics. The company’s products include enzymes, proteins, antibodies, and nucleic acids used in research and development, drug discovery, and diagnostic applications. Takara Bio also offers agricultural products, such as plant growth regulators and soil amendments. In addition, the company provides contract research and development services.
– Forward Pharma A/S ($NASDAQ:FWP)
Write a paragraph on it’s market cap and ROE and a brief intro of what the company does:
Forward Pharma A/S has a market cap of 22.41M as of 2022, a Return on Equity of -3.32%. The Company is focused on developing and commercializing therapies for the treatment of inflammatory diseases.
– Obio Technology (shanghai) Corp Ltd ($SHSE:688238)
Obio Technology (shanghai) Corp Ltd is a publicly traded company with a market cap of 11.59B as of 2022. The company has a return on equity of 2.0%. The company is engaged in the business of providing technology solutions to businesses and consumers. The company’s products and services include software, hardware, and services. The company’s customers include businesses of all sizes, government entities, and individual consumers.
Summary
Maravai LifeSciences has recently seen a cut to neutral by Credit Suisse due to slowing growth in their stock. With this in mind, investors should consider the company’s current financial position and its potential for future growth. To begin with, Maravai has a strong balance sheet and a healthy cash flow, allowing them to pay down debt and continue to invest in new products and services.
Additionally, the company has a wide range of products and services that cater to life sciences, medical device, and healthcare research industries. This breadth of offerings could provide opportunities for further growth in the coming years. As such, investors should weigh the financials, product portfolio, and competitive landscape before deciding on whether to invest in Maravai LifeSciences.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
